Meeting
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
Authors
Curtis Andrew Lachowiez
M.D. Anderson Cancer Center, Houston, TX
Curtis Andrew Lachowiez , Gautam Borthakur , Sanam Loghavi , Zhihong Zeng , Tapan M. Kadia , Lucia Masarova , Koichi Takahashi , George Dono Tippett , Samantha Smith , Jacqueline Suen Garcia , Prithviraj Bose , Elias Jabbour , Farhad Ravandi , Naval Guastad Daver , Guillermo Garcia-Manero , Bilyana Stoilova , Paresh Vyas , Hagop M. Kantarjian , Marina Konopleva , Courtney Denton Dinardo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03471260
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7012)
DOI
10.1200/JCO.2021.39.15_suppl.7012
Abstract #
7012
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda
Poster
2021 ASCO Annual Meeting
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.
First Author: Jacqueline Suen Garcia
Poster
2020 ASCO Virtual Scientific Program
Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.
First Author: Abhishek Maiti